Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Conditional Approval Recommended for Use of Epogin for Myocardial Infarction as Kohdo-iryo
March 28, 2011
- NEW PRODUCTS
March 28, 2011
- DSP to Collaborate with Kyoto Univ. in Cancer Field
March 28, 2011
- Sanko Junyaku to Market RDKK's Cobas h 232 Series from April
March 28, 2011
- Nippon Shinyaku Aims at Sales of ¥5.2 Bil. for Vidaza
March 28, 2011
- TS-1 Approved for Advanced Stomach Cancer in Europe: Taiho
March 28, 2011
- Daiichi Sankyo to Promote MEMARY Both in 1st Line Therapy and Combination
March 28, 2011
- Japanese Market for Antimicrobials to Contract to US$3 Bil. in 2019: Datamonitor
March 28, 2011
- Baxter's PREFLUCEL Approved in 13 EU Countries
March 28, 2011
- Operations Remain Suspended at Many Drug Production Facilities 1 Week after Disaster
March 28, 2011
- Citigroup Sees Strong Outlook for Nippon Shinyaku's Vidaza
March 21, 2011
- Pfizer, Daiichi Sankyo Alert Med. Institutions about Use of Prevnar, ActHIB
March 21, 2011
- Januvia Ranked No. 1 in HP, GP Markets: RepTrack Survey
March 21, 2011
- JMA Urges Korosho to Make Quick Decision Regarding ActHIB, Prevnar
March 21, 2011
- Massive Earthquake, Tsunami Hit Northern Japan Paralyzing Business Activities
March 21, 2011
- ActHIB Recalled due to Contamination
March 21, 2011
- Nihon Medi-Physics Provides Radiocesium Decontaminating Agent Free of Charge
March 21, 2011
- Applications Expected for Inactivated Polio Vaccines at End of 2011
March 21, 2011
- R&I to Downgrade Terumo Following Announcement of Acquisition of CaridianBCT
March 21, 2011
- Korosho to Extend HPV Vaccination Period for Girls Currently in 1st Grade of Senior High School
March 21, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…